Drug discovery

#Drug development #Drug discovery #Target validation

Evotec milestones in Bristol Myers Squibb collaboration

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated their long-term strategic… Read More

#News

#Biotechnology #Drug development #Drug discovery #Health #Life sciences #Narrated podcasts #Pharmaceutical

2030 Life Sciences and Health in the Digital Age (Part 1)

This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on… Read More

#Podcasts

#Antibody #Biologics #Drug discovery #High throughput screening

PerkinElmer invests in Carterra, antibody screening and characterisation expert

Carterra, specialist in label-free high throughput antibody screening and characterisation, has closed on a round of equity financing led by PerkinElmer. Current Carterra investors Telegraph Hill Partners and Ballast Point Ventures also participated in the financing round. The Carterra LSA platform for accelerating the discovery of therapeutic antibodies has become… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery

2020 overview for AI for drug discovery, biomarker development and advanced R&D

Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and… Read More

#Editor's Choice #Market Reports #News

#Assay development & optimisation #Drug discovery

Event for assay developers, screening scientists and drug discovery research scientists

We understand the importance of kinetic assay design. In the upcoming DDW collaboration, supported by SPT Labtech, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience, will share his pharmacology expertise to explain how to produce assays that deliver hits with higher physiological relevance. Due to popularity we have opened up… Read More

#Editor's Choice #News

#Drug discovery #Drug targets

Webinar: Hit discovery for trained immunity and tolerance

Do you want to learn about: Trained immunity The role of epigenetic targets in trained immunity Hit discovery through ultra-high throughput screening of large libraries Industry standard Hit-to-Lead biological profiling frameworks Join Dr. Saman Honarnejad, Director Drug Discovery at Pivot Park Screening Centre​ on 14 December 3PM (GMT) for this… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery

Project produces next-generation AI drug discovery platform

The consortium behind the DeepADMET project set up to advance artificial intelligence (AI) technologies for drug discovery, has announced the successful conclusion of this project which was funded by Innovate UK, the UK’s innovation agency. Optibrium – a developer of software for drug discovery, Intellegens – an AI company, and… Read More

#News

#Assay development & optimisation #Drug discovery

Industry insight on designing assays that deliver hits with higher physiological relevance

DDW is delighted to announce an exclusive event, supported by SPT Labtech, that will allow you to gain knowledge on kinetic assay design and take this forward to produce assays that deliver hits with higher physiological relevance. Pharmacology expert Dr Nick Holliday, chief scientific officer, Excellerate Bioscience, will lead this… Read More

#Editor's Choice #News

#Covid-19 #Drug discovery #Therapeutics

New flu therapy may help against COVID-19

A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists. In an average year, more than 2 million people in the United States are hospitalised with the flu, and 30,000 to… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Drug discovery

Biosero and TetraScience R&D data update accelerates drug discovery

Biosero and TetraScience have revealed that they will integrate data glyphs, instruments and robotic sensors with the cloud-native Tetra Data Platform using Green Button Go Automation Scheduling Software. Together the systems will automatically collect, store and harmonize life science R&D data in the cloud to accelerate drug discovery and research. Read More

#News

#Biotechnology #Drug development #Drug discovery #Life sciences #Narrated podcasts #Pharmaceutical #Research

Evolution of User Experience for life sciences

Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to… Read More

#Podcasts

#Assay development & optimisation #Drug discovery

Pharmacology expert explains how to improve the drug discovery process

In an exclusive event for DDW, Dr Holliday, Chief Scientific Officer, Excellerate Bioscience, will focus on the importance of kinetic assays in drug discovery. What you will learn: How association and dissociation rate constants describe compound binding kinetics The potential clinical benefits of optimising kinetic constants when compound profiling The… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Oncology #Therapeutics

Lantern Pharma AI milestone will cut cost, time and risk in developing new drug therapies

Lantern Pharma has reached a significant milestone by surpassing one billion curated data points on its RADR platform, a total it believes is the most amassed by any company in the biotech sector. The milestone, which was reached well ahead of schedule, enables new opportunities in Lantern’s work to identify and… Read More

#News

#Assay development optimisation & technology #Drug discovery

Why kinetic assays are important to drug discovery

In this free webinar, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience will provide exclusive insight into the importance of kinetic assays in the drug discovery process. Viewers will gain knowledge on kinetic assay design and how to design assays that deliver hits with higher physiological relevance. Putting the dynamics… Read More

#Editor's Choice #News

#Biotechnology #Drug development #Drug discovery #Ingredients / APIs / Fine chemicals #Pharmacokinetics / Pharmacodynamics

Evotec expands UK site into drug discovery & development centre

Evotec is expanding its campus in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for… Read More

#News